焦慮及憂鬱症治療市場:現狀分析與預測(2021年～2027年)

全球焦慮及憂鬱症治療的市場規模，在預測期間(2021年～2027年)預計以約3％的年複合成長率擴大。急速發展的新藥，和人們對精神障礙嚴重度的認識高漲，促進焦慮及憂鬱症治療市場成長。

本報告提供全球焦慮及憂鬱症治療市場相關調查，市場現狀，以及各藥物類型，各流通管道，各疾病類型，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場簡介

第2章 調查手法或假設

第3章 市場摘要

第4章 摘要整理

第5章 COVID-19對全球焦慮及憂鬱症治療市場的影響

第6章 全球焦慮及憂鬱症治療市場收益，2019年～2027年

第7章 各藥物類型的市場洞察

• 抗憂鬱症藥
• 抗痙攣藥
• 非典型抗精神病藥物
• 苯重氮基鹽
• β- 阻斷劑

第8章 各流通管道的市場洞察

• 院內藥局
• 零售藥局
• 線上藥局

第9章 各疾病類型的市場洞察

• 重度憂鬱症(MDD)
• OCD
• 恐懼症
• PTSD
• 其他

第10章 各地區的市場洞察

• 北美
• 歐洲
• 亞太地區
• 其他地區

第11章 焦慮及憂鬱症治療市場市場動態

• 市場促進因素
• 市場課題
• 影響分析

第12章 焦慮及憂鬱症治療市場機會

第13章 焦慮及憂鬱症治療市場趨勢

第14章 相關法規

第15章 需求面與供給方面的分析

• 需求面分析
• 供給方面分析

第16章 價值鏈分析

第17章 競爭模式

• 競爭情形
  • 波特的五力分析

第18章 企業概要

• GlaxoSmithKline plc
• Pfizer Inc.
• Eli Lilly and Company
• H. Lundbeck A/S
• Forest Laboratories Inc.
• AstraZeneca
• Merck & Company Inc.
• Johnson & Johnson
• Sanofi-Aventis
• Lupin ltd

第19章 免責聲明

The global anxiety and depression treatment market is anticipated to grow with an elevated CAGR of around 3% over the forecast period (2021-2027). Anxiety and Depression are the most common mental disorders where the melancholy mood lasts for a long duration. Thus, affects the overall efficiency of the person, and depression is directly linked with stress and anxiety. The long term anxiety is considered one of the symptoms of depression.

The rapidly developing novel drugs and rising awareness about the severity of mental disorders among people contribute to the significant market growth of the anxiety and depression treatment market. The changing lifestyle preferences such as consumption of the substance and problems like insomnia are the major factors contributing to the increasing number of depression cases. Moreover, the increasing unemployment around the globe is also responsible for the increasing stress and anxiety levels among the youths resulting in the increasing demand for better treatment of anxiety and depression. As per the international labor organization, the global unemployment rate is increasing by 6.7% annually.

GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly and Company, H. Lundbeck A/S, Forest Laboratories, Inc., AstraZeneca, Merck & Company, Inc., Johnson & Johnson, and Sanofi-Aventis are some of the prominent players operating in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with new varieties of anxiety and depression treatments.

Insights Presented in the Report

"Amongst Drug Type, anti-depressant drug segment holds the major share"

Based on drug types, the anxiety and depression treatment market is segmented into antidepressants, anticonvulsants, atypical antipsychotics, benzodiazepines, and Beta-blockers. The anti-depressant drug class is expected to have significant growth during the forecast period owing to the continuous development and approval of the new medications for the treatment of anxiety and depression. For instance, in April 2022, Lupin Ltd received approval from the US health regulator to market its generic version of Desvenlafaxine extended-release tablets used for treating depression.

"Amongst distribution channels, online channel segment holds the major share"

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online channels. Amongst them, the online pharmacies distribution channel is expected to witness significant growth due to the rising investment in e-pharmacy across the world. However, anxiety and depression drugs are mostly available only through prescription. Thus, doctors are now preferring e-prescriptions to allow patients to get easy access to medicine with the help of e-prescriptions. Countries, like the United Kingdom, are putting more effort into the implementation of e-prescriptions. For instance, the electronic prescription service (EPS) will be rolled out across England after a trial run in 60 GP practices and hundreds of pharmacies, in 2019. National Health Service (NHS) aimed to save USD 373 million in the next two years.

Amongst disorder types, the major depressive disorder segment holds the major share"

Based on the disorder type, the market is segmented into major depressive disorder (MDD), OCD, phobia, PTSD, and others. Among them, the market for major depressive disorder is expected to witness significant growth. The growth of the segmented is mainly attributed to the increasing level of workplace stress and the number of suffering people along with a lack of the appropriate knowledge about the severity of the diseases leads to the development of stress into major depressive disorder. According to the American workplace and NIOSH Reports, 80% of workers feel stress on the job among them 40% of workers reported their job was very or extremely stressful.

"North America represents one of the largest markets of Anxiety and Depression Treatment market"

For a better understanding of the market dynamics of the Anxiety and Depression Treatment market, a detailed analysis was conducted for different regions across the globe including North America (U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. In 2020, North America accounted for the majority share in the market. The increasing number of awareness programs by the governments is driving the market for anxiety and depression disorders in the region. Canada, for instance, launched the mental illness awareness week in October 2021 to educate people about mental health and its effects.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Customization Options:

The global anxiety and depression treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stake Holders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Anxiety and Depression Treatment Market
• 2.2. Research Methodology of the Anxiety and Depression Treatment Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Anxiety and Depression Treatment Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET COVID-19 IMPACT

6 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY DRUG TYPE

• 7.1. Antidepressants
• 7.2. Anticonvulsants
• 7.3. Atypical antipsychotics
• 7.4. Benzodiazepines
• 7.5. Beta-blockers

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Hospital Pharmacies
• 8.2. Retail Pharmacies
• 8.3. Online Pharmacies

9 MARKET INSIGHTS BY DISORDER TYPE

• 9.1. Major Depressive Disorder (MDD)
• 9.2. OCD
• 9.3. Phobia
• 9.4. PTSD
• 9.5. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. United States
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. France
  • 10.2.3. U.K.
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia Pacific
• 10.4. Rest of World

11 ANXIETY AND DEPRESSION TREATMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ANXIETY AND DEPRESSION TREATMENT MARKET OPPORTUNITIES

13 ANXIETY AND DEPRESSION TREATMENT MARKET TRENDS

14 LEGAL & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. GlaxoSmithKline plc
• 18.2. Pfizer Inc.
• 18.3. Eli Lilly and Company
• 18.4. H. Lundbeck A/S
• 18.5. Forest Laboratories Inc.
• 18.6. AstraZeneca
• 18.7. Merck & Company Inc.
• 18.8. Johnson & Johnson
• 18.9. Sanofi-Aventis
• 18.10. Lupin ltd

19 DISCLAIMER